Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke.
OBJECTIVE
A method for identifying patients at increased risk for developing secondary hemorrhagic transformation (HT) after acute ischemic stroke could be of significant value, particularly in patients being considered for thrombolytic therapy. We hypothesized that diffusion-weighted MRI might aid in the identification of such patients.


METHODS
We retrospectively analyzed 17 patients with ischemic stroke who received diffusion-weighted MRI within 8 hours of symptom onset and who also received follow-up neuroimaging within 1 week of initial scan. The apparent diffusion coefficient (ADC) for each pixel in the whole ischemic area was calculated, generating a histogram of values. Areas subsequently experiencing HT were then compared with areas not experiencing HT to determine the relationship between ADC and subsequent HT.


RESULTS
A significantly greater percentage of pixels possessed lower ADCs (</=550x10(-)(6) mm(2)/s) in HT lesions compared with non-HT lesions (47% versus 19%; P:<0.001). Moreover, >40% of the pixels possessed values </=550x10(-)(6) mm(2)/s in all lesions experiencing secondary HT, compared with <31% of the pixels in the non-HT-destined lesions.


CONCLUSIONS
HT-destined stroke regions possess a significantly great percentage of low ADC values than non-HT-destined regions. Early measurement of ADC values may be a useful tool for assessing secondary HT risk.
Tong
D C
DC
Stanford Stroke Center, Palo Alto, Calif, USA. dct@leland.Stanford.edu
Adami
A
A
Moseley
M E
ME
Marks
M P
MP
D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000175:diagnosis* / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D015994:Incidence; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000175:diagnosis* / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000009:adverse effects; D014057:Tomography, X-Ray Computed